Becker Ventures
Becker Ventures is a family-owned conglomerate based in Troy, Michigan, specializing in investment services across various sectors, including manufacturing, real estate, and hospitality. Established in 1998, the company has developed a diverse portfolio that encompasses investments in physical therapy services and other industries. With a dedicated team of 14 employees, Becker Ventures focuses on identifying and nurturing opportunities that align with its investment strategy, while maintaining a commitment to growth and sustainability in the sectors it operates within.
At CGC Genomics (CGC) we are deeply committed to advancing the field of cancer care through complex, precision genomics analysis and report interpretation. We distill complex genomic data into concise, actionable insights for healthcare providers, reducing interpretation times and facilitating timely, personalized treatment recommendations for 10 million patients with metastatic cancer. Our years of experience interpreting and supporting thousands of the most complicated cancer genomics cases around the world enables CGC to offer healthcare providers timely, expert cancer genomics analysis and consultation support, delivering world-class expertise wherever and whenever needed.
Velicept Therapeutics, Inc. is a clinical development company focused on creating innovative treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS). Founded in 2015 and based in Malvern, Pennsylvania, the company is advancing its lead program, solabegron, a novel compound that selectively relaxes bladder smooth muscle by stimulating beta 3-adrenoceptors. This approach aims to address unmet medical needs and improve the quality of life for patients suffering from these conditions. Velicept Therapeutics operates as a portfolio company of NeXeption, emphasizing its commitment to developing best-in-class therapeutic options.
AltheRx Pharmaceuticals is a privately held clinical development company established in 2010, dedicated to advancing innovative compounds in significant unmet medical markets. The company specializes in the clinical development and commercialization of its lead product, Solabegron, a novel adrenoceptor agonist aimed at treating overactive bladder (OAB) and irritable bowel syndrome (IBS). These conditions impact the quality of life for over 90 million Americans, a figure expected to rise with an aging population. Solabegron was initially discovered and developed by GlaxoSmithKline before being acquired by AltheRx in 2011. The company's leadership team possesses extensive experience in the pharmaceutical and biotechnology sectors, positioning AltheRx to optimize its development efforts through strategic partnerships.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.